Oncology — Revenue
Eli Lilly Oncology — Revenue decreased by 13.0% to $2.27B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 16.4%, from $1.95B to $2.27B. Over 4 years (FY 2021 to FY 2025), Oncology — Revenue shows an upward trend with a 13.0% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
Rising revenue suggests strong demand and effective commercial execution in the oncology space, whereas declining revenue may suggest market saturation or the impact of generic/biosimilar competition.
Detailed definition
This metric measures the net revenue recognized from sales of oncology-related pharmaceutical products to unaffiliated t...
Peer comparison
Standardized across the pharmaceutical industry as the primary revenue line item for specific therapeutic business segments.
lly_segment_oncology_revenueHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.55B | $1.41B | $1.41B | $1.35B | $1.37B | $1.29B | $1.65B | $1.36B | $1.67B | $1.75B | $1.88B | $1.81B | $2.16B | $2.23B | $2.55B | $1.95B | $2.41B | $2.41B | $2.61B | $2.27B |
| QoQ Change | — | -9.5% | +0.2% | -4.0% | +1.2% | -5.5% | +27.7% | -17.9% | +23.2% | +4.6% | +7.8% | -3.9% | +19.3% | +3.4% | +14.4% | -23.7% | +23.9% | -0.2% | +8.3% | -13.0% |
| YoY Change | — | — | — | — | -11.9% | -8.0% | +17.2% | +0.2% | +22.1% | +35.1% | +14.1% | +33.5% | +29.2% | +27.7% | +35.5% | +7.6% | +11.8% | +7.9% | +2.1% | +16.4% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Eli Lilly's oncology — revenue?
- Eli Lilly (LLY) reported oncology — revenue of $2.27B in Q1 2026.
- How has Eli Lilly's oncology — revenue changed year-over-year?
- Eli Lilly's oncology — revenue increased by 16.4% year-over-year, from $1.95B to $2.27B.
- What is the long-term trend for Eli Lilly's oncology — revenue?
- Over 4 years (2021 to 2025), Eli Lilly's oncology — revenue has grown at a 13.0% compound annual growth rate (CAGR), from $5.74B to $9.38B.
- What does oncology — revenue mean?
- The net revenue generated from external sales of cancer treatments.